Literature DB >> 18852122

Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.

Myles C Hodgson1, Howard C Shen, Anthony N Hollenberg, Steven P Balk.   

Abstract

Androgen receptor (AR) recruitment of transcriptional corepressors NCoR and SMRT can be enhanced by antagonists such as mifepristone. This study shows that enhanced NCoR binding to the mifepristone-liganded AR is mediated by the NCoR COOH-terminal N1 CoRNR box and that this selectivity is due to charged residues unique to the COOH-terminal CoRNR boxes of NCoR and SMRT. Significantly, these residues are on a helical face adjacent to oppositely charged residues in helix 4 of the AR ligand-binding domain. Mutagenesis of these AR residues in helix 4, as well as mutation of lysine 720 in helix 3 (predicted to interact with the CoRNR box), markedly impaired AR recruitment of NCoR, indicating that N1 CoRNR box binding is being stabilized by these ionic interactions in the AR ligand-binding domain coactivator/corepressor binding site. Finally, results using a helix 12-deleted AR indicate that mifepristone induces allosteric changes in addition to helix 12 displacement that are critical for NCoR binding. These findings show that AR antagonists can enhance corepressor recruitment by stabilizing a distinct antagonist conformation of the AR coactivator/corepressor binding site and support the development of additional antagonists that may be able to further enhance AR recruitment of corepressors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852122      PMCID: PMC2587007          DOI: 10.1158/1535-7163.MCT-08-0461

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  49 in total

1.  The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors.

Authors:  X Hu; M A Lazar
Journal:  Nature       Date:  1999-11-04       Impact factor: 49.962

2.  Mechanism of corepressor binding and release from nuclear hormone receptors.

Authors:  L Nagy; H Y Kao; J D Love; C Li; E Banayo; J T Gooch; V Krishna; K Chatterjee; R M Evans; J W Schwabe
Journal:  Genes Dev       Date:  1999-12-15       Impact factor: 11.361

3.  Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression.

Authors:  L Alland; R Muhle; H Hou; J Potes; L Chin; N Schreiber-Agus; R A DePinho
Journal:  Nature       Date:  1997-05-01       Impact factor: 49.962

4.  Molecular basis of agonism and antagonism in the oestrogen receptor.

Authors:  A M Brzozowski; A C Pike; Z Dauter; R E Hubbard; T Bonn; O Engström; L Ohman; G L Greene; J A Gustafsson; M Carlquist
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

5.  The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.

Authors:  T A Jackson; J K Richer; D L Bain; G S Takimoto; L Tung; K B Horwitz
Journal:  Mol Endocrinol       Date:  1997-06

6.  The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor.

Authors:  B L Wagner; J D Norris; T A Knotts; N L Weigel; D P McDonnell
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

7.  Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase.

Authors:  L Nagy; H Y Kao; D Chakravarti; R J Lin; C A Hassig; D E Ayer; S L Schreiber; R M Evans
Journal:  Cell       Date:  1997-05-02       Impact factor: 41.582

8.  The nuclear corepressors recognize distinct nuclear receptor complexes.

Authors:  R N Cohen; A Putney; F E Wondisford; A N Hollenberg
Journal:  Mol Endocrinol       Date:  2000-06

9.  FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor.

Authors:  B He; J A Kemppainen; E M Wilson
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

10.  Molecular determinants for the tissue specificity of SERMs.

Authors:  Yongfeng Shang; Myles Brown
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

View more
  26 in total

Review 1.  Disruption of androgen receptor signaling in males by environmental chemicals.

Authors:  Doug C Luccio-Camelo; Gail S Prins
Journal:  J Steroid Biochem Mol Biol       Date:  2011-04-13       Impact factor: 4.292

2.  SMRTε, a corepressor variant, interacts with a restricted subset of nuclear receptors, including the retinoic acid receptors α and β.

Authors:  Brenda J Mengeling; Michael L Goodson; William Bourguet; Martin L Privalsky
Journal:  Mol Cell Endocrinol       Date:  2012-01-12       Impact factor: 4.102

3.  Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation.

Authors:  Michael L Goodson; Brenda J Mengeling; Brian A Jonas; Martin L Privalsky
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

Review 4.  Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Authors:  David Lorente; Joaquin Mateo; Zafeiris Zafeiriou; Alan D Smith; Shahneen Sandhu; Roberta Ferraldeschi; Johann S de Bono
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

5.  Binding of bisphenol A, bisphenol AF, and bisphenol S on the androgen receptor: Coregulator recruitment and stimulation of potential interaction sites.

Authors:  Lalith Perera; Yin Li; Laurel A Coons; Rene Houtman; Rinie van Beuningen; Bonnie Goodwin; Scott S Auerbach; Christina T Teng
Journal:  Toxicol In Vitro       Date:  2017-07-24       Impact factor: 3.500

6.  In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.

Authors:  Howard C Shen; Kumaran Shanmugasundaram; Nicholas I Simon; Changmeng Cai; Hongyun Wang; Sen Chen; Steven P Balk; Alan C Rigby
Journal:  Mol Endocrinol       Date:  2012-09-28

7.  Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.

Authors:  Grant Buchanan; Eleanor F Need; Jeffrey M Barrett; Tina Bianco-Miotto; Vanessa C Thompson; Lisa M Butler; Villis R Marshall; Wayne D Tilley; Gerhard A Coetzee
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

Review 8.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

Review 9.  Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Authors:  Karen E Knudsen; Howard I Scher
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

10.  Mechanism of androgen receptor corepression by CKβBP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer.

Authors:  Jiann-An Tan; Suxia Bai; Gail Grossman; Mark A Titus; O Harris Ford; Elena A Pop; Gary J Smith; James L Mohler; Elizabeth M Wilson; Frank S French
Journal:  Mol Cell Endocrinol       Date:  2013-10-05       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.